Curanex Pharmaceuticals Inc (NASDAQ:CURX) Short Interest Update

Curanex Pharmaceuticals Inc (NASDAQ:CURX) was the target of a large decrease in short interest during the month of August. As of August 31st, there was short interest totaling 449 shares, a decrease of 98.2% from the August 15th total of 24,375 shares. Based on an average daily trading volume, of 35,024 shares, the short-interest ratio is currently 0.0 days. Currently, 0.0% of the shares of the company are sold short.

Curanex Pharmaceuticals Price Performance

CURX traded up $0.04 during trading on Friday, hitting $4.34. The stock had a trading volume of 2,361 shares, compared to its average volume of 84,130. The company has a 50 day moving average price of $4.36 and a 200-day moving average price of $6.47. Curanex Pharmaceuticals has a one year low of $3.58 and a one year high of $183.59. The firm has a market cap of $6.82 million and a price-to-earnings ratio of -0.56.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Curanex Pharmaceuticals stock. Citadel Advisors LLC purchased a new stake in Curanex Pharmaceuticals Inc (NASDAQ:CURX) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 64,067 shares of the company’s stock, valued at approximately $46,000.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Curanex Pharmaceuticals in a research report on Wednesday, July 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

About Curanex Pharmaceuticals

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.